BETA: Please send your feedback!
Madrigal Pharmaceuticals
MDGL:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2021
—
About
Pharmaceuticals: Other
Founded 2011
Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. The company offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal Pharmaceuticals was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
website
Headquarters
Executives
| Name | Title | Gender |
| Paul A. Friedman, MD | Chairman, President & Chief Executive Officer | Male |
| Marc R. Schneebaum, CPA | Chief Financial Officer & Senior Vice President | Male |
| Rebecca A. Taub, MD | Director & Chief Medical Officer | Female |
| Edward Chiang | Founder | Male |
Mindful Investing Summary
Madrigal Pharmaceuticals - Competitors and Related Companies
How Madrigal Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Madrigal Pharmaceuticals
MDGL:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2021
—
Loading…